AVITA Medical Gestion

Gestion contrôle des critères 1/4

Le PDG AVITA Medical est Jim Corbett, nommé en Sep2022, a un mandat de 2.17 ans. La rémunération annuelle totale est $ 2.07M, composée du salaire de 30.2% et des bonus 69.8%, y compris les actions et options de la société. détient directement 0.033% des actions de la société, d'une valeur de A$ 173.97K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 6.1 ans.

Informations clés

Jim Corbett

Directeur général

US$2.1m

Rémunération totale

Pourcentage du salaire du PDG	30.2%
Durée du mandat du directeur général	2.2yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	1.8yrs
Durée moyenne du mandat des membres du conseil d'administration	6.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jim Corbett a-t-elle évolué par rapport aux bénéfices de AVITA Medical?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$57m
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$2m	US$625k	-US$35m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$157k	-US$27m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$256k	n/a	-US$25m

Rémunération vs marché: La rémunération totale de Jim ($USD 2.07M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 910.58K ).

Rémunération et revenus: La rémunération de Jim a augmenté alors que l'entreprise n'est pas rentable.

PDG

Jim Corbett (66 yo)

2.2yrs

Titularisation

US$2,068,675

Compensation

Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
James Corbett	CEO, President & Executive Director	2.2yrs	US$2.07m	0.033% A$ 174.0k
David O'Toole	Chief Financial Officer	1.4yrs	US$2.18m	pas de données
David Fencil	Senior Vice President of Global Operations	1.8yrs	pas de données	pas de données
Katie Bush	Senior Vice President of Scientific & Medical Affairs	less than a year	pas de données	pas de données
Jessica Ekeberg	Investor Relations Executive	no data	pas de données	pas de données
Nicole Kelsey	Chief Legal & Compliance Officer and Corporate Secretary	less than a year	pas de données	pas de données
Debbie Garner	Senior Vice President of Global Marketing & Strategy	6.3yrs	pas de données	pas de données
Rob Hall	Senior Vice President of Human Resources	1.8yrs	pas de données	pas de données
Niraj Doshi	Senior Vice President of Product Development & Program Management	1.8yrs	pas de données	pas de données
Ron Lagerquist	Senior Vice President of Quality Assurance & Regulatory Affairs	1.8yrs	pas de données	pas de données
Robin VanDenburgh	Senior Vice President of U.S. Commercial Sales	less than a year	pas de données	pas de données

1.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de AVH n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
James Corbett	CEO, President & Executive Director	3.3yrs	US$2.07m	0.033% A$ 174.0k
Jan Reed	Independent Non-Executive Director	3.3yrs	US$211.12k	0.11% A$ 578.5k
Jeremy Curnock-Cook	Independent Non-Executive Director	12.1yrs	US$199.87k	0.079% A$ 412.7k
Fiona Wood	Founder and Member of Clinical Advisory Board	8.8yrs	US$29.80k	pas de données
Louis Panaccio	Independent Non-Executive Chairman	10.3yrs	US$234.69k	0.16% A$ 864.4k
Robert McNamara	Independent Non-Executive Director	1.6yrs	US$369.11k	0.075% A$ 393.1k
Cary Vance	Independent Non-Executive Director	1.6yrs	US$364.94k	0.037% A$ 192.9k
Suzanne Crowe	Independent Non-Executive Director	8.8yrs	US$195.28k	0.10% A$ 545.1k

6.1yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AVH sont considérés comme expérimentés (ancienneté moyenne 6.1 ans).

AVITA Medical Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

Recent updates

AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces FDA Approval of RECELL GO

AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024

AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024

AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023

AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC

New minor risk - Shareholder dilution

New minor risk - Profitability

AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022)

AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go

AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

First quarter 2023 earnings released: US$0.073 loss per share (vs US$0.076 loss in 1Q 2022)

AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023

AVITA Medical, Inc. Announces Executive Changes

Full year 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in FY 2021)

AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo

AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

AVITA Medical, Inc. Revises Financial Guidance for the Year 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair

AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces Chief Executive Officer Changes

AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions

RECELL Insurance Coverage Begins in Japan for Acute Burns

Second quarter 2022 earnings released: US$0.05 loss per share (vs US$0.038 loss in 2Q 2021)

AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System

AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index

Avita Medical, Inc. Provides Guidance for Year 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

Forecast to breakeven in 2024

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022

Forecast to breakeven in 2024

AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy

Forecast to breakeven in 2024

AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo

First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.095 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.41 loss in FY 2020)

AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022

FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment

AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021

Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021

U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.053 loss per share (vs US$0.14 loss in 3Q 2020)

AVITA Medical, Inc. Provides Earnings Guidance for 2021

AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time

AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021